컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Academy of Neurology (EAN) Congress 2025

21 June - 24 June, 2025, Finland

Daridorexant benefits women with insomnia during menopausal transition

2025-10-01

Treatment with daridorexant improved sleep outcomes and daytime functioning in women with insomnia disorder during the menopausal transition, according to a study presented at EAN 2025.
Preventive fremanezumab sustains reductions in migraine days up to 2 years in real world

2025-10-01

In the final analysis of the real-world PEARL study presented at EAN 2025, fremanezumab as a preventive treatment for chronic or episodic migraine halves the number of monthly migraine days or more from 3 months onwards through 24 months
GLP-1RAs may provide migraine relief independent of weight loss

2025-10-01

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have the potential to reduce the frequency of migraines even in patients who do not lose weight—an effect that may be related to a reduction in intracranial pressure, according to a pilot prospective observational study.
Natalizumab, ocrelizumab equally effective in multiple sclerosis

2025-10-01

In patients with relapsing or progressing multiple sclerosis (MS), clinical outcomes are similar following treatment with natalizumab vs ocrelizumab, according to a retrospective study.
Vorasidenib helps prevent seizures in grade 2 mIDH1/2 gliomas

2025-10-01

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.
Eptinezumab eases migraine, medication-overuse headache

2025-10-01

Two separate randomized controlled trials (SUNRISE and RESOLUTION) have shown the superiority of eptinezumab over placebo in a predominantly Asian migraine population and in patients with chronic migraine (CM) and medication-overuse headache (MOH).
Common blood test predicts which AD patients will have rapid cognitive decline

2025-10-01

Insulin resistance, detected through the routine triglyceride-glucose (TyG) index, identifies individuals with early Alzheimer’s disease (AD) who are four times more likely to experience rapid cognitive decline, findings from a new study presented at EAN 2025 suggest.
Cenobamate cuts SUDEP risk

2025-10-01

A study presented at EAN 2025 demonstrates a reduction in the risk of sudden unexpected death in epilepsy (SUDEP) following treatment with the antiseizure medication (ASM) cenobamate among Spanish individuals in the phase III C021 study. The reductions were based on SUDEP-3 and SUDEP-7 risk scores.
Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

2025-10-01

Individuals with tardive dyskinesia (TD) report favourable outcomes with the VMAT2 inhibitor deutetrabenazine in an age subgroup analysis.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브